Top

BMC Endocrine Disorders

Published in:

Open Access 01-12-2023 | Glimepiride | Research

Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial

Authors: Rehab H. Werida, Aalaa Ramzy, Youssri Nassief Ebrahim, Maged Wasfy Helmy

Published in: BMC Endocrine Disorders | Issue 1/2023

Abstract

Background and objective

Type 2 diabetes mellitus (T2DM) is caused by insulin resistance or tissue insensitivity to insulin, as well as relative insulin insufficiency. Diabetes that is uncontrolled for an extended period of time is linked to substantial comorbidities and organ damage. The purpose of the current study is to assess the effect of coadministration of omega-3 fatty acids with glimepiride on blood glucose, lipid profile, serum irisin, and sirtuin-1 levels in T2DM patients.

Methods

This clinical trial involved 70 type 2 diabetic patients randomly assigned to glimepiride 3 mg with either omega-3 capsules contained fish oil 1000 mg, 13% of eicosapentaenoic acid (EPA) and 9% docosahexaenoic acid (DHA) (omega-3 group, n = 35) or placebo capsules contained corn oil and linoleic acid (control group, n = 35) daily for three months. Blood samples were obtained at the start of the study and 12 weeks later for biochemical examination of HbA1c%, FBG, fasting insulin, and lipid profile. In addition, the atherogenic index of plasma (AIP) was calculated. Human enzyme-linked immunosorbent assay (ELISA) kits were utilized for assessing serum irisin and sirtuin-1 levels before and after the intervention.

Results

Compared to the control group, omega-3 fatty acids decreased serum fasting blood glucose (FBG, p < 0.001), glycated hemoglobin percent (HbA1C%, p < 0.001), total cholesterol (TC, p < 0.001), triglycerides (TGs, p = 0.006), low density lipoprotein (LDL, p = 0.089), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR, p = 0.021) after three months of intervention. However, a significant increase was reported in serum irisin and high density lipoprotein (HDL) between both groups after intervention (p = 0.026 and p = 0.007, respectively). The atherogenic index of plasma (AIP) increased in the control group but decreased in the omega-3 group, with significant differences between the two groups (p < 0.001).

Conclusion

The present study found that supplementing with omega-3 fatty acids might dramatically enhance blood irisin levels, as well as improve glycemic control and lipid profile in type 2 diabetes mellitus patients using glimepiride.

Trial Registration

This study is registered on ClinicalTrials.gov under identifier NCT03917940. (The registration date: April 17, 2019).

Ansari S, Djalali M, Mohammadzadeh Honarvar N, et al. The effect of n-3 polyunsaturated fatty acids supplementation on serum irisin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Int J Endocrinol Metab. 2017;15(1):e40614. https://doi.org/10.5812/ijem.40614.CrossRefPubMedPubMedCentral

Ighbariya A, Weiss R. Insulin resistance, prediabetes, metabolic syndrome: what should every pediatrician know? J Clin Res Pediatr Endocrinol. 2017;9(Suppl 2):49–57. https://doi.org/10.4274/jcrpe.2017.S005.CrossRefPubMedPubMedCentral

Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. https://doi.org/10.1038/sigtrans.2017.23.CrossRefPubMedPubMedCentral

Kitada M, Ogura Y, Monno I, Koya D. Sirtuins and type 2 diabetes: role in inflammation, oxidative stress, and mitochondrial function. Front Endocrinol (Lausanne). 2019;27(10):187. https://doi.org/10.3389/fendo.2019.00187.CrossRef

Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8. https://doi.org/10.1038/nature10777.CrossRefPubMedPubMedCentral

Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369–80. https://doi.org/10.1038/sj.emboj.7600244.CrossRefPubMedPubMedCentral

Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012;8:463–72. https://doi.org/10.2147/HIV.S33194.CrossRefPubMedPubMedCentral

Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications. 2004;18(6):367–76. https://doi.org/10.1016/j.jdiacomp.2004.07.001.CrossRefPubMed

Jun JE, Jeong IK, Yu JM, et al. Efficacy and safety of omega-3 fatty acids in patients treated with statins for residual hypertriglyceridemia: a randomized, double-blind, Placebo-Controlled Clinical Trial. Diabetes Metab J. 2020;44(1):78–90. https://doi.org/10.4093/dmj.2018.0265.CrossRefPubMed

10.

Souza DR, Pieri BLDS, Comim VH, et al. Fish oil reduces subclinical inflammation, insulin resistance, and atherogenic factors in overweight/obese type 2 diabetes mellitus patients: a pre-post pilot study. J Diabetes Complications. 2020;34(5):107553. https://doi.org/10.1016/j.jdiacomp.2020.107553.CrossRefPubMed

11.

Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 2012;33(4):436–43. https://doi.org/10.1093/eurheartj/ehr362.CrossRefPubMed

12.

Valle Flores JA, Fariño Cortéz JE, Mayner Tresol GA, Perozo Romero J, Blasco Carlos M, Nestares T. Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis. Appl Physiol Nutr Metab. 2020;45(8):805–11. https://doi.org/10.1139/apnm-2019-0729.CrossRefPubMed

13.

International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327–34. https://doi.org/10.2337/dc09-9033.CrossRef

14.

Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. Int J Epidemiol. 2014;43(3):655–65. https://doi.org/10.1093/ije/dyu058.CrossRefPubMed

15.

Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19(5):476–82.CrossRefPubMed

16.

Allian CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–5.CrossRef

17.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.CrossRefPubMed

18.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9. https://doi.org/10.1007/BF00280883. PMID: 3899825.CrossRefPubMed

19.

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34(7):583–8. https://doi.org/10.1016/s0009-9120(01)00263-6. PMID: 11738396.CrossRefPubMed

20.

Sangeda RZ, Mosha F, Prosperi M, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035. https://doi.org/10.1186/1471-2458-14-1035.CrossRefPubMedPubMedCentral

21.

Khalili L, Valdes-Ramos R, Harbige LS. Effect of n-3 (Omega-3) polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers and body weight in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of RCTs. Metabolites. 2021;11(11):742. https://doi.org/10.3390/metabo11110742.CrossRefPubMedPubMedCentral

22.

Sarbolouki S, Javanbakht MH, Derakhshanian H, et al. Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial. Singapore Med J. 2013;54(7):387–90. https://doi.org/10.11622/smedj.2013139.CrossRefPubMed

23.

Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Conjugated linoleic acid or omega 3 fatty acids increase mitochondrial biosynthesis and metabolism in skeletal muscle cells. Lipids Health Dis. 2012;11:142. https://doi.org/10.1186/1476-511X-11-142.CrossRefPubMedPubMedCentral

24.

Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr. 2012;142(3):592S-599S. https://doi.org/10.3945/jn.111.155259.CrossRefPubMed

25.

Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V. Effects of n-3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr. 2006;84(3):540–50. https://doi.org/10.1093/ajcn/84.3.540.CrossRefPubMed

26.

Sirtori CR, Crepaldi G, Manzato E, et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis. 1998;137(2):419–27. https://doi.org/10.1016/s0021-9150(97)00298-0. PMID: 9622285.CrossRefPubMed

27.

Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71(5):1085–94. https://doi.org/10.1093/ajcn/71.5.1085.CrossRefPubMed

28.

Kabir M, Skurnik G, Naour N, et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr. 2007;86(6):1670–9. https://doi.org/10.1093/ajcn/86.5.1670.CrossRefPubMed

29.

Thota RN, Acharya SH, Garg ML. Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial. Lipids Health Dis. 2019;18(1):31. https://doi.org/10.1186/s12944-019-0967-x.CrossRefPubMedPubMedCentral

30.

Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18. https://doi.org/10.1056/NEJMoa1203859.CrossRefPubMed

31.

Kesavulu MM, Kameswararao B, Apparao Ch, Kumar EG, Harinarayan CV. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab. 2002;28(1):20–6.PubMed

32.

Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87(6):1981S-S1990. https://doi.org/10.1093/ajcn/87.6.1981S. PMID: 18541599.CrossRefPubMed

33.

Eftekhari MH, Aliasghari F, Beigi MA, Hasanzadeh J. The effect of conjugated linoleic acids and omega-3 fatty acids supplementation on lipid profile in atherosclerosis. Adv Biomed Res. 2014;3:15. https://doi.org/10.4103/2277-9175.124644. PMID:24600599;PMCID:PMC3929013.CrossRefPubMedPubMedCentral

34.

Agh F, Mohammadzadeh Honarvar N, Djalali M, et al. Omega-3 fatty acid could increase one of myokines in male patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial. Arch Iran Med. 2017;20(1):28–33 PMID: 28112528.PubMed

35.

Novelle MG, Contreras C, Romero-Picó A, López M, Diéguez C. Irisin, two years later. Int J Endocrinol. 2013;2013:746281. https://doi.org/10.1155/2013/746281. PMID:24298283;PMCID:PMC3835481.CrossRefPubMedPubMedCentral

36.

Werida RH, Abou-Madawy S, Abdelsalam M, Helmy MW. Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients. Clin Exp Med. 2022;22(2):301–10. https://doi.org/10.1007/s10238-021-00740-w. PMID: 34286397.CrossRefPubMed

37.

Mostafa TM, El-Gharbawy NM, Werida RH. Circulating IRAPe, irisin, and IL-34 in relation to insulin resistance in patients with type 2 diabetes. Clin Ther. 2021;43(7):e230–40. https://doi.org/10.1016/j.clinthera.2021.05.003. PMID: 34103176.CrossRefPubMed

38.

Gizaw M, Anandakumar P, Debela T. A Review on the role of irisin in insulin resistance and type 2 diabetes mellitus. J Pharmacopuncture. 2017;20(4):235–42. https://doi.org/10.3831/KPI.2017.20.029. Retraction in: JPharmacopuncture.2020;23(1):42-43.PMID:30151293;PMCID:PMC6104716.CrossRefPubMedPubMedCentral

39.

Liu S, Du F, Li X, Wang M, Duan R, Zhang J, Wu Y, Zhang Q. Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic β cells. PLoS ONE. 2017;12(4):e0175498. https://doi.org/10.1371/journal.pone.0175498. PMID:28394923;PMCID:PMC5386279.CrossRefPubMedPubMedCentral

40.

Son SH, Lee SM, Lee MH, Son YK, Kim SE, An WS. Omega-3 fatty acids upregulate SIRT1/3, activate PGC-1α via deacetylation, and induce Nrf1 production in 5/6 nephrectomy rat model. Mar Drugs. 2021;19(4):182. https://doi.org/10.3390/md19040182. PMID:33810216;PMCID:PMC8066610.CrossRefPubMedPubMedCentral

41.

Savchenko LG, Digtiar NI, Selikhova LG, Kaidasheva EI, Shlykova OA, Vesnina LE, Kaidashev IP. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom J Intern Med. 2019;57(3):233–40. https://doi.org/10.2478/rjim-2019-0003. PMID: 30901315.CrossRefPubMed

42.

Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58(12):2718–25. https://doi.org/10.2337/db09-1003. PMID:19940235;PMCID:PMC2780862.CrossRefPubMedPubMedCentral

43.

Strycharz J, Rygielska Z, Swiderska E, Drzewoski J, Szemraj J, Szmigiero L, Sliwinska A. SIRT1 as a therapeutic target in diabetic complications. Curr Med Chem. 2018;25(9):1002–35. https://doi.org/10.2174/0929867324666171107103114. PMID: 29110598.CrossRefPubMed

44.

Elnaem MH, Mansour NO, Nahas AF, Baraka MA, Elkalmi R, Cheema E. Renal outcomes associated with the use of non-insulin antidiabetic pharmacotherapy: a review of current evidence and recommendations. Int J Gen Med. 2020;13:1395–409. https://doi.org/10.2147/IJGM.S285191. PMID:33324086;PMCID:PMC7733337.CrossRefPubMedPubMedCentral

45.

Berbari AE. Links between chronic kidney disease and cardiovascular disease: a bidirectional relationship In: Cardiorenal Syndrome: Mechanisms, Risk and Treatment. Springer Milan; 2010:3–14. https://doi.org/10.1007/978-88-470-1463-3_1

Title: Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial
Authors: Rehab H. Werida
Aalaa Ramzy
Youssri Nassief Ebrahim
Maged Wasfy Helmy
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Glimepiride
Insulins
Insulins
Type 2 Diabetes
Published in: BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-023-01511-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and objective

Methods

Results

Conclusion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 1/2023

What is the effect of mobile phone text message reminders on medication adherence among adult type 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials

Operative treatment of cystic prolactinomas: a retrospective study

Heterogeneity and associated factors of patients with polycystic ovary syndrome health behaviors: a latent class analysis

Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes

Association between the MCP-1 -2518 A > G (rs1024611) polymorphism and susceptibility to type 2 diabetes mellitus and diabetic nephropathy: a meta-analysis

The effect of Curcumin on metabolic parameters and androgen level in women with polycystic ovary syndrome: a randomized controlled trial

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials